Alligator Bioscience AB (FRA:7AL0) Beneish M-Score: 144.29 (As of Jun. 26, 2026)


FRA:7AL0 Alligator Bioscience AB FRA:7AL0
39 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Beneish M-Score?

Alligator Bioscience AB FRA:7AL0 39 Beneish M-Score is 144.29 as of Jun. 26, 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 831 Biotechnology companies, Alligator Bioscience AB ranks worse than 98.8% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 144.29 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Alligator Bioscience AB's Beneish M-Score or its related term are showing as below:

FRA:7AL0' s Beneish M-Score Range Over the Past 10 Years
Min: -5.15   Med: -2.14   Max: 144.29
Current: 144.29

During the past 12 years, the highest Beneish M-Score of Alligator Bioscience AB was 144.29. The lowest was -5.15. And the median was -2.14.


Alligator Bioscience AB Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Beneish M-Score Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.97 -2.21 -5.15 -3.90 144.29

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 144.29 0.00

FRA:7AL0 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Beneish M-Score falls into.


FRA:7AL0
39GF Score
Alligator Bioscience AB FRA:7AL0
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Alligator Bioscience AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 157.7984+0.528 * 1+0.404 * 1.2634+0.892 * 0.0094+0.115 * 0.7696
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.945986-0.327 * 0.4166
=145.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €0.22 Mil.
Revenue was €0.05 Mil.
Gross Profit was €0.05 Mil.
Total Current Assets was €6.31 Mil.
Total Assets was €10.16 Mil.
Property, Plant and Equipment(Net PPE) was €0.17 Mil.
Depreciation, Depletion and Amortization(DDA) was €-0.94 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €7.18 Mil.
Long-Term Debt & Capital Lease Obligation was €2.35 Mil.
Net Income was €-4.72 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-14.33 Mil.
Total Receivables was €0.15 Mil.
Revenue was €5.02 Mil.
Gross Profit was €5.02 Mil.
Total Current Assets was €6.21 Mil.
Total Assets was €9.07 Mil.
Property, Plant and Equipment(Net PPE) was €0.26 Mil.
Depreciation, Depletion and Amortization(DDA) was €4.24 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €17.51 Mil.
Long-Term Debt & Capital Lease Obligation was €2.91 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.223 / 0.047) / (0.151 / 5.022)
=4.744681 / 0.030068
=157.7984

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5.022 / 5.022) / (0.047 / 0.047)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6.31 + 0.172) / 10.164) / (1 - (6.207 + 0.263) / 9.071)
=0.362259 / 0.286738
=1.2634

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.047 / 5.022
=0.0094

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.236 / (4.236 + 0.263)) / (-0.942 / (-0.942 + 0.172))
=0.941543 / 1.223377
=0.7696

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 0.047) / (0 / 5.022)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.352 + 7.181) / 10.164) / ((2.91 + 17.513) / 9.071)
=0.937918 / 2.251461
=0.4166

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4.719 - 0 - -14.334) / 10.164
=0.945986

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Alligator Bioscience AB has a M-score of 145.59 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 144.29 mean?
Alligator Bioscience AB (FRA:7AL0) has a Beneish M-Score of 144.29 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #821 out of 831 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Alligator Bioscience AB's Beneish M-Score too high?
Alligator Bioscience AB's current Beneish M-Score is 144.29. Based on the distribution chart, Alligator Bioscience AB ranks #821 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alligator Bioscience AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #821 out of 831 companies for Beneish M-Score. This places Alligator Bioscience AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Beneish M-Score is 144.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Beneish M-Score of 144.29. The current Beneish M-Score is 144.29. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Beneish M-Score is 144.29 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for FRA:7AL0

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price